The public comment window on the FDA's proposal to keep semaglutide, tirzepatide, and liraglutide off the 503B Bulks List closed at 11:59 p.m. Eastern on July 30, 2026. The administrative record for that rulemaking is now shut. The Federal Register notice was explicit about it: "late, untimely filed comments will not be considered."
That record turned out to be unusually large, and unusually back-loaded. Counting public submissions posted to docket FDA-2018-N-3240 since the proposal published on May 1, we make it 3,901 — of which roughly 84 percent arrived only after the FDA granted a 30-day extension. What happens next is not a vote and not an announcement; it is the FDA reading 3,901 filings and deciding whether to finalize as proposed.
Research-context information only. This article reports on published regulatory documents and public docket records. Nothing here is medical or legal advice. Semaglutide, tirzepatide, and liraglutide are FDA-approved as prescription medicines; the research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity, or potency in that channel. Other compounds referenced or surfaced on this page — including retatrutide, cagrilintide, and survodutide — are investigational and are not approved for any use in humans in the United States. Consult a licensed physician for personal medical decisions.
What actually closed
The proposal itself is narrow and worth stating precisely, because it is widely described in shorthand that overstates it.
On May 1, 2026, the FDA published a notice at 91 FR 23431 identifying three bulk drug substances it "has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide." That list is the register of active pharmaceutical ingredients for which the agency has found a clinical need for outsourcing facilities to compound from bulk.
Under section 503B(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act, an outsourcing facility may not compound using a bulk drug substance unless one of two things is true: the substance appears on the 503B Bulks List, or the drug compounded from it is on the FDA shortage list at the time of compounding, distribution, and dispensing. Tirzepatide came off the shortage list in December 2024 and semaglutide followed in February 2025, which is what makes the bulks-list question live for those two. Liraglutide injection has remained on the shortage list, which is the separate door it has been going through.
The timeline, from the primary documents:
| Date | Document | What it did |
|---|---|---|
| May 1, 2026 | 91 FR 23431 (FDA-2018-N-3240) | Proposed not to include semaglutide, tirzepatide, liraglutide; comments due June 30 |
| June 26, 2026 | 91 FR 38719 | Extended the comment period 30 days "in response to a request for an extension"; new deadline July 30 |
| July 30, 2026, 11:59 p.m. ET | — | Electronic filing system stopped accepting comments |
| Next | FDA review | No decision announced; no timeline announced |
The extension carried the record
We queried the regulations.gov API against docket FDA-2018-N-3240 on August 1, 2026 and counted public submissions by posted date. The distribution is lopsided:
| Window | Public submissions posted | Share of record |
|---|---|---|
| May 1 – June 29, 2026 (original window) | 624 | 16% |
| June 30 – July 30, 2026 (extension window) | 3,277 | 84% |
| Total since the proposal published | 3,901 | 100% |
Within that, 1,771 submissions — about 45 percent of the entire record — posted in the eight days from July 24 through July 31 alone.
Two caveats on those numbers, stated plainly. First, regulations.gov reports posted date, not submitted date, and posting lags submission by days as filings clear moderation; the final tally will rise. Second, FDA-2018-N-3240 is the standing 503B Bulks List docket rather than a docket opened solely for this proposal, so a small number of submissions in the window may address other nominated substances. The counts above are what the docket holds for the period, not a certified tally of GLP-1-specific comments.
The shape is still the story. A 60-day federal comment window drew 624 filings. A 30-day extension drew 3,277. That is not what a routine technical docket looks like — it is what happens when an organized constituency finds the docket late and files into it.
The named filings on the record run in both directions. The Partnership for Safe Medicines filed on July 28 (FDA-2018-N-3240-0377) supporting the exclusion, arguing it would protect patient safety and the integrity of the drug approval process. The Alliance for Pharmacy Compounding, the trade association for outsourcing facilities, took the opposite posture from the day the proposal landed, saying publicly that it "does not change the status quo" and committing to file substantive comments. Both positions are now in the administrative record, which is also the record any subsequent judicial review would be decided on.
What the rule would and would not touch
If the FDA finalizes as proposed, the effect is bounded, and the bounds matter more than the headline.
Would change: 503B outsourcing facilities would lose the bulks-list route for these three molecules permanently — not contingently on a future shortage. That closes the high-volume channel that supplied much of the low-cost compounded GLP-1 market during the 2023–2025 shortage era.
Would not change: 503A pharmacies compounding against an individual patient prescription operate under a different section of the statute and are not the subject of this notice. Our explainer on why one pharmacy will compound a peptide and another won't walks through where the 503A and 503B lines actually fall.
Also would not change: the research-use-only vendor channel. The 503B Bulks List governs starting materials for registered outsourcing facilities producing compounded prescription drugs. It is a different regulatory object entirely from research-grade material, and a final rule here would not alter its status, availability, or pricing. Per-mg pricing and COA documentation by vendor are on the semaglutide and tirzepatide pages, with current vendor codes on the deals page.
